Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular and Clinical Oncology
Join Editorial Board Propose a Special Issue
Print ISSN: 2049-9450 Online ISSN: 2049-9469
Journal Cover
November-2017 Volume 7 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
November-2017 Volume 7 Issue 5

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Clinical characteristics of critically ill cancer patients who are undergoing isolated limb perfusion

  • Authors:
    • Silvio A. Ñamendys-Silva
    • Arturo M. Ruiz-Beltran
    • Mireya Barragán‑Dessavre
    • Andoreni R. Bautista-Ocampo
    • Abelardo Meneses-García
    • Octavio González-Chon
    • Angel Herrera-Gómez
  • View Affiliations / Copyright

    Affiliations: Department of Critical Care Medicine, Instituto Nacional de Cancerología, Mexico City 14080, Mexico, Department of Critical Care Medicine, Fundación Clínica Médica Sur, Mexico City 14050, Mexico
    Copyright: © Ñamendys-Silva et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Pages: 747-750
    |
    Published online on: August 31, 2017
       https://doi.org/10.3892/mco.2017.1401
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

The aim of the present study was to investigate the incidence of organ dysfunction, and to describe the clinical characteristics and intensive care unit (ICU) outcomes of critically ill cancer patients who were admitted to an oncological ICU during the isolated limb perfusion post-operative period. The present study was an observational investigation of 42 critically ill cancer patients who were admitted to the ICU of the Instituto Nacional de Cancerología, during the isolated limb perfusion post-operative period, between July 2010 and February 2016. The mean age of the patients was 45.7±16.9 years, and 45.2% (19 cases) were female. Soft tissue sarcoma was the most common pre-operative diagnosis (38.1%), and the mean duration of surgery was 267.6±50.1 min. Furthermore, a mean blood loss volume of 732.3±526.1 ml during the procedure was recorded, and the patients received a mean volume of 3.88±1.28 l crystalloid fluid during the surgical procedure, subsequently requiring an additional 2.95±6.28 l on the first post-operative day. The incidence of organ dysfunction was 90.5% and was most frequently noted in the respiratory (81%), hepatic (33%), hematologic (31%) and renal (11.9%) systems. No patients succumbed to the disease during the ICU and hospital stay. Nevertheless, <10% of the patients required vasopressors. Additionally, <5% of the patients required invasive mechanical ventilation. Therefore, ICU admission directly following isolated limb perfusion should not be standardized.

Introduction

Since it was introduced in 1957, isolated limb perfusion has been an available therapeutic option for patients with locally advanced neoplasia, such as melanoma and sarcoma (1,2). Isolation of the affected limb allows for the administration of high doses of chemotherapeutic agents, eliminating their associated severe systemic effects (1,2). For this procedure, an extracorporeal circulation circuit is employed that incorporates a pump and an oxygenator to warm the perfusion solution and to enhance oxygen pressure prior to its administration (3). Melphalan and tumor necrosis factor α (TNFα), used either alone or in combination, are the cytotoxic agents of choice, and can be administered at doses ≥15–20 times the doses that are tolerated after systemic administration (4). A potential hazard that can occur during the procedure is the leaking of these agents into the systemic circulation (5). Nevertheless, the most common frequent adverse effects present locally, and consist of edema, erythema and unusual cases of neuropathy and vascular complications (5).

TNFα is a pleiotropic cytokine that is capable of destroying tumor neoangiogenic vessels (6,7). Nevertheless, it is also involved in sepsis-induced cardiovascular dysfunction (6,7). Systemic toxicity appears to be associated with the amount of leakage of these cytotoxic agents into the systemic circulation, and it is recommended that the procedure be stopped when this amount exceeds 10% (8). When it appears, systemic toxicity is usually limited, consisting of nausea and post-operative emesis, as well as transitory myelosuppression (4). However, due to the potential toxicity of these treatments, patients are often subject to invasive hemodynamic monitoring (4).

The aim of the present study was to investigate the incidence of organ dysfunction, and to describe the clinical characteristics and intensive care unit (ICU) outcomes of critically ill cancer patients who were admitted to an oncological ICU during the period following surgical isolated limb perfusion.

Patients and methods

The present study was an observational and qualitative investigation of 42 critically ill cancer patients who were admitted to the ICU of the Instituto Nacional de Cancerología. All consecutive who were admitted to the ICU during the isolated limb perfusion post-operative period were included, between July 2010 and February 2016.

The chemotherapeutic agents used included TNFα and melphalan. Demographical, clinical and pathological data were collected from each patient on the first day following ICU admission, including the following: Location of the primary tumor; comorbidity; surgical duration; perioperative bleeding volume; crystalloid fluid volume required during the surgical procedure. In addition, during the initial 24 h of ICU admission, the following data were recorded: Complications (medical and surgical); mechanical ventilation and vasopressor therapy requirements and duration periods; ICU and hospital length of stay; ICU and hospital mortality rates due to any cause. Organ dysfunction was defined according to the Mexican Sequential Organ Failure Assessment (MEXSOFA) score as ≥1 point for any organ system (9).

Additionally, the Acute Physiology and Chronic Health Evaluation II and MEXSOFA scores were calculated using the poorest acute physiological variable values obtained during the first 24 h of ICU admission (10). Systemic inflammatory response syndrome was defined as two or more of the following: i) Temperature >38°C or <36°C; ii) heart rate >90/min; iii) respiratory rate >20/min or PaCO2 <32 mm Hg (4.3 kPa); iv) white blood cell count >12,000/mm3 or <4,000/mm3 or >10% immature bands (11). Subsequently, the patients were divided into two groups according to the number of organ system dysfunctions (≤1 organ dysfunction, n=21; ≥2 organ dysfunctions, n=21). The patients were followed-up for one year after discharge from the ICU. Patients were considered lost to follow-up if they had not visited the hospital for 90 days. The Bioethics Committee of The Instituto Nacional de Cancerología approved the present study, and the requirement to obtain informed consent was waived.

Statistical analysis. Categorical data are expressed as percentages. Continuous variables are expressed as the mean ± standard deviation. All continuous variables were analyzed for normality using the Kolmogorov-Smirnoff test and compared by performing a Student's t-test. All statistical analyses were performed using SPSS version 22.0 (IBM Corp., Armonk, NY, USA). Two-sided P<0.05 values were considered to indicate a statistically significant difference.

Results

The mean age of the patients was 45.7±16.9 years, and 45.2% (19 cases) were female. Soft tissue sarcoma was the most common pre-operative diagnosis (38.1%), and the mean duration of surgery was 267.6±50.1 min. Furthermore, a mean blood loss volume of 732.3±526.1 ml was recorded during the procedure; the patients received a mean peri-operative volume of 3.88±1.28 liters crystalloid fluid and required an additional 2.95±6.28 liters on the first post-operative day (Table I).

Table I.

Patient demographic and clinical data

Table I.

Patient demographic and clinical data

CharacteristicsValues
Total patients, n (%)42 (100)
Age, yearsa45.7±16.9
Sex, n (%)
  Female19 (45.2)
  Male23 (54.8)
APACHE II scorea9.1±3.3
MEXSOFA scoreb3 (2–4)
Diagnosis, n (%)
  Sarcoma16 (38.1)
  Liposarcoma8 (19)
  Melanoma7 (16.7)
  Fibromatosis5 (11.9)
  Squamous cell carcinoma2 (4.8)
  Neurogenic sarcoma1 (2.4)
  Myxofibrosarcoma1 (2.4)
  Fibroblastoma1 (2.4)
  Merkel cell carcinoma1 (2.4)
Duration of surgery, mina267.6±50.1
TNFα administration, n (%)37 (88)
Perioperative bleeding, mla732.3±526.1
Vasopressors, n (%)4 (9.5)
Invasive mechanical ventilation, n (%)2 (4.7)
Crystalloid fluid received, litersa
  During surgery3.88±1.28
  Following admission to the ICU2.95±6.28
Length of stay in the ICU, daysa1 (0–1)

a Data are presented as the mean ± standard deviation.

b Data are presented as the median (interquartile range). APACHE, acute physiology and chronic health evaluation; MEXSOFA, Mexican sequential organ failure assessment; TNFα, tumor necrosis factor α; ICU, intensive care unit.

During the initial 24 h following admission to the ICU, four patients required vasopressors (9.5%) and two patients required invasive mechanical ventilation (4.7%) for a mean duration of one day. Furthermore, 21.4% of the patients exhibited systemic inflammatory response syndrome.

Overall, 23 patients (54%) required packed red blood cell transfusions. Additionally, the incidence of organ dysfunction was 90.5% and was most frequently noted in the respiratory (81%), hepatic (33%), hematologic (31%) and renal (11.9%) systems (Table II). Five of the patients (11.9%) exhibited renal dysfunction; however, no patients required or received renal replacement therapy. During the ICU and hospital stay, no patients were recorded as having succumbed to the disease. After one year of follow-up, all patients remained alive. In total, 4.7% of patients (2/42) were lost to follow-up, according to the aforementioned criterion.

Table II.

Patients according to the number of dysfunctional organ systems.

Table II.

Patients according to the number of dysfunctional organ systems.

Organ dysfunction

Variables≤1 (n=21)≥2 (n=21)P-value
Hemoglobin, g/la10.39±1.410.07±1.670.513
Platelets, ×109/lb189 (174–233)138 (120–157) <0.001c
White blood cells, ×109/la17.9±5.917.1±4.30.735
Creatinine, mg/dlb0.65 (0.61–0.84)0.78 (0.63–0.99)0.217
Albumin, mg/dla2.49±0.392.49±0.650.980
Total bilirubin, mg/dlb0.9 (0.7–1.2)1.2 (1.0–1.7)0.032c
pHb7.31 (7.30–7.37)7.32 (7.30–7.37)0.800
Bicarbonate, mEq/lb19.7 (18.0–22.1)20.0 (19.0–21)0.504
Lactate, mmol/lb2.4 (2.18–3.2)2.4 (1.3–2-6)0.231
Sodium, mEq/la137.4±2.39138.3±2.70.264
Potassium, mEq/lb3.9 (3.7–4.0)3.8 (3.6–4.2)0.604
Chloride, mEq/la110.4±3.8112.3±3.80.129
Calcium, mg/dla7.31±0.496.85±1.580.307
Phosphorus, mg/dlb3.3 (3.1–3.6)3.1 (2.8–3.9)0.571
Magnesium, mEq/la1.62±0.461.59±0.280.828

a Data presented as the mean ± standard deviation.

b Data presented as the median (interquartile range).

c P<0.05. ICU, intensive care unit.

Discussion

Isolated limb perfusion using TNFα has previously been associated with major systemic changes that are characterized by a septic-like shock syndrome (12,13). In the current study, the incidence of organ dysfunction was 90.5% in critically ill cancer patients who were admitted to the ICU during the isolated limb perfusion post-operative period, being most frequently noted in the respiratory, hepatic and coagulation systems.

Laurenzi et al (14) reported that 17% of observed critically ill patients developed severe respiratory and cardiovascular toxicity; of these patients, all required mechanical ventilation and 11% required vasoactive treatment (14). In the present study, <10% of the patients required vasopressors and <5% required invasive mechanical ventilation. All patients were extubated during the first day on the ICU.

In contrast to prior studies, the current study did not report the volume of drug leakage from the limb to the systemic circulation, which is reportedly correlated with the degree of systemic toxicity (8,15). It is notable that isolated limb perfusion is stopped when the leakage from the limb to the systemic circulation reaches 5% when using TNFα, or 10% when using melphalan in the Instituto Nacional de Cancerología.

The primary limitations of the present study were that it represented the experience of a single oncological ICU and that the sample size was small.

In conclusion, a high incidence of organ dysfunction was observed. Nevertheless, <5% of the patients required invasive mechanical ventilation and <10% required vasopressors. Therefore, ICU admission directly following isolated limb perfusion should not be standardized.

Acknowledgements

The present authors thank the ICU nurses and medical staff of the Instituto Nacional de Cancerología who were involved in the care of the study patients. The present study was supported by institutional funds.

References

1 

Smith HG, Cartwright J, Wilkinson MJ, Strauss DC, Thomas JM and Hayes AJ: Isolated Limb Perfusion with Melphalan and Tumour Necrosis Factor α for In-Transit Melanoma and Soft Tissue Sarcoma. Ann Surg Oncol. 22 Suppl 3:S356–S361. 2015. View Article : Google Scholar : PubMed/NCBI

2 

Nieweg OE and Kroon BB: Isolated limb perfusion with melphalan for melanoma. J Surg Oncol. 109:332–337. 2014. View Article : Google Scholar : PubMed/NCBI

3 

Ruschulte H, Shi S, Tseng WW, Kolodzie K, Crawford PC, Schneider DB, Kashani-Sabet M, Minor D, Apfel C and Leong SP: Anesthesia management of patients undergoing hyperthermic isolated limb perfusion with melphalan for melanoma treatment: An analysis of 17 cases. BMC Anesthesiol. 13:152013. View Article : Google Scholar : PubMed/NCBI

4 

Bhangu A, Broom L, Nepogodiev D, Gourevitch D and Desai A: Outcomes of isolated limb perfusion in the treatment of extremity soft tissue sarcoma: A systematic review. Eur J Surg Oncol. 39:311–319. 2013. View Article : Google Scholar : PubMed/NCBI

5 

Vrouenraets BC, Kroon BB, Ogilvie AC, van Geel AN, Nieweg OE, Swaak AJ and Eggermont AM: Absence of severe systemic toxicity after leakage-controlled isolated limb perfusion with tumor necrosis factor-α and melphalan. Ann Surg Oncol. 6:405–412. 1999. View Article : Google Scholar : PubMed/NCBI

6 

Saíd HM, Gómez AH, Ponce JLA and Jaime G: Perfusión Aislada de Extremidad. Una Alternativa a la Amputación en Tumores Avanzados por Melanoma, Sarcomas y Otros Tumores Irresecables de las Extremidades. Med Sr. 9:148–155. 2002.

7 

Eggimann P, Chioléro R, Chassot PG, Lienard D, Gerain J and Lejeune F: Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest. 107:1074–1082. 1995. View Article : Google Scholar : PubMed/NCBI

8 

Paulsen IF, Chakera AH, Schmidt G, Drejøe J, Klyver H, Oturai PS, Hesse B, Drzewiecki K and Mortensen J: Radionuclide leakage monitoring during hyperthermic isolated limb perfusion for treatment of local melanoma metastasis in an extremity. Clin Physiol Funct Imaging. 35:301–305. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Ñamendys-Silva SA, Silva-Medina MA, Vásquez-Barahona GM, Baltazar-Torres JA, Rivero-Sigarroa E, Fonseca-Lazcano JA and Domínguez-Cherit G: Application of a modified sequential organ failure assessment score to critically ill patients. Braz J Med Biol Res. 46:186–193. 2013. View Article : Google Scholar : PubMed/NCBI

10 

Knaus WA, Draper EA, Wagner DP, Zimmerman JE and Apache II: APACHE II: A severity of disease classification system. Crit Care Med. 13:818–829. 1985. View Article : Google Scholar : PubMed/NCBI

11 

Bone RC, Balk RA, Cerra FB, et al: American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med. 20:864–874. 1992. View Article : Google Scholar : PubMed/NCBI

12 

Lienard D, Ewalenko P, Delmotte JJ, Renard N and Lejeune FJ: High-dose recombinant tumor necrosis factor alpha in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol. 10:52–60. 1992. View Article : Google Scholar : PubMed/NCBI

13 

Vaglini M, Belli F, Ammatuna M, Inglese MG, Manzi R, Prada A, Persiani L, Santinami M, Santoro N and Cascinelli N: Treatment of primary or relapsing limb cancer by isolation perfusion with high-dose alpha-tumor necrosis factor, gamma-interferon, and melphalan. Cancer. 73:483–492. 1994. View Article : Google Scholar : PubMed/NCBI

14 

Laurenzi L, Natoli S, Di Filippo F, Calamaro A, Centulio F, Anzà M, Cavaliere F, Marcelli ME, Garinei R and Arcuri E: Systemic and haemodynamic toxicity after isolated limb perfusion (ILP) with TNF-α. J Exp Clin Cancer Res. 23:225–231. 2004.PubMed/NCBI

15 

Christoforidis D, Chassot PG, Mosimann F, Lienard D, Brunstein F, Bejko D, Lejeune FJ and Chiolero R: Isolated limb perfusion: Distinct tourniquet and tumor necrosis factor effects on the early hemodynamic response. Arch Surg. 138:17–25. 2003. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Ñamendys-Silva SA, Ruiz-Beltran AM, Barragán‑Dessavre M, Bautista-Ocampo AR, Meneses-García A, González-Chon O and Herrera-Gómez A: Clinical characteristics of critically ill cancer patients who are undergoing isolated limb perfusion. Mol Clin Oncol 7: 747-750, 2017.
APA
Ñamendys-Silva, S.A., Ruiz-Beltran, A.M., Barragán‑Dessavre, M., Bautista-Ocampo, A.R., Meneses-García, A., González-Chon, O., & Herrera-Gómez, A. (2017). Clinical characteristics of critically ill cancer patients who are undergoing isolated limb perfusion. Molecular and Clinical Oncology, 7, 747-750. https://doi.org/10.3892/mco.2017.1401
MLA
Ñamendys-Silva, S. A., Ruiz-Beltran, A. M., Barragán‑Dessavre, M., Bautista-Ocampo, A. R., Meneses-García, A., González-Chon, O., Herrera-Gómez, A."Clinical characteristics of critically ill cancer patients who are undergoing isolated limb perfusion". Molecular and Clinical Oncology 7.5 (2017): 747-750.
Chicago
Ñamendys-Silva, S. A., Ruiz-Beltran, A. M., Barragán‑Dessavre, M., Bautista-Ocampo, A. R., Meneses-García, A., González-Chon, O., Herrera-Gómez, A."Clinical characteristics of critically ill cancer patients who are undergoing isolated limb perfusion". Molecular and Clinical Oncology 7, no. 5 (2017): 747-750. https://doi.org/10.3892/mco.2017.1401
Copy and paste a formatted citation
x
Spandidos Publications style
Ñamendys-Silva SA, Ruiz-Beltran AM, Barragán‑Dessavre M, Bautista-Ocampo AR, Meneses-García A, González-Chon O and Herrera-Gómez A: Clinical characteristics of critically ill cancer patients who are undergoing isolated limb perfusion. Mol Clin Oncol 7: 747-750, 2017.
APA
Ñamendys-Silva, S.A., Ruiz-Beltran, A.M., Barragán‑Dessavre, M., Bautista-Ocampo, A.R., Meneses-García, A., González-Chon, O., & Herrera-Gómez, A. (2017). Clinical characteristics of critically ill cancer patients who are undergoing isolated limb perfusion. Molecular and Clinical Oncology, 7, 747-750. https://doi.org/10.3892/mco.2017.1401
MLA
Ñamendys-Silva, S. A., Ruiz-Beltran, A. M., Barragán‑Dessavre, M., Bautista-Ocampo, A. R., Meneses-García, A., González-Chon, O., Herrera-Gómez, A."Clinical characteristics of critically ill cancer patients who are undergoing isolated limb perfusion". Molecular and Clinical Oncology 7.5 (2017): 747-750.
Chicago
Ñamendys-Silva, S. A., Ruiz-Beltran, A. M., Barragán‑Dessavre, M., Bautista-Ocampo, A. R., Meneses-García, A., González-Chon, O., Herrera-Gómez, A."Clinical characteristics of critically ill cancer patients who are undergoing isolated limb perfusion". Molecular and Clinical Oncology 7, no. 5 (2017): 747-750. https://doi.org/10.3892/mco.2017.1401
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team